Nektar Therapeutics officer and director Howard Robin filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 429 shares of Nektar common stock on NASDAQ.

Key Highlights

  • Proposed sale: Howard Robin, listed as both an officer and director of Nektar Therapeutics, proposes to sell 429 shares of common stock.
  • Aggregate market value: The 429 shares carry an aggregate market value of $15,378.49, according to the filing.
  • Source of shares: The shares were acquired on November 13, 2026, through restricted stock vesting from the issuer, with payment classified as compensation.
  • Tax-related purpose: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
  • Prior sales activity: The filing discloses a prior sale of 418 shares of common stock on August 18, 2026, with gross proceeds of $30,086.93.
  • Shares outstanding: Nektar Therapeutics had 34,214,683 shares of common stock outstanding at the time of the filing.
  • Broker: The proposed sale is to be executed through Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island.

Nektar Therapeutics Officer Proposes Tax-Cover Share Sale Following Restricted Stock Vesting

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission on November 17, 2026, Howard Robin, who holds roles as both an officer and a director at Nektar Therapeutics (NASDAQ:NKTR), intends to sell 429 shares of the company's common stock. The filing attributes the approximate date of sale as November 17, 2026, with the transaction to be conducted on NASDAQ through Fidelity Brokerage Services LLC.

The filing discloses that the 429 shares were obtained via restricted stock vesting on November 13, 2026, with the issuer, Nektar Therapeutics, identified as the party from whom the securities were acquired. The nature of payment is listed as compensation. As noted in the remarks section of the filing, the proposed sale is specifically intended to cover a tax obligation arising from the settlement of a vested equity award distribution.

In connection with the three-month sales history required by Form 144, the filing reports that Howard Robin sold 418 shares of Nektar common stock on August 18, 2026, generating gross proceeds of $30,086.93. The company's registered address, as listed in the filing, is 455 Mission Bay Boulevard South, San Francisco, California 94158. The SEC file number for Nektar Therapeutics is listed as 000-24006.

What Was Disclosed

Howard Robin, an officer and director at Nektar Therapeutics, filed a Form 144 notice proposing to sell 429 shares of common stock valued at $15,378.49, acquired through restricted stock vesting on November 13, 2026, with the stated purpose of covering a related tax obligation.